Franziska Erlmeier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Franziska Erlmeier has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Arndt Hartmann
Mitglied des Bridge Consortiums
5 shared publicationsSandra Steffens
Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster
5 shared publicationsMichael Autenrieth
Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany
4 shared publicationsWilko Weichert
Institute for Pathology and Pathological Anatomy, Technische Universität München, Trogerstraße 18, 81675, Munich, Germany
4 shared publicationsMax Wiedemann
The Munich Cancer Registry of the Tumorzentrum Munich, Institute of Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany
3 shared publications- Philipp Ivanyi
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
3 shared publications
Latest Publications
- 3 August 2017
- Published by Georg Thieme Verlag KG in TumorDiagnostik & Therapie
- Vol. 38 (06) , 381-385
c-Met Onkogen bei Nierenzellkarzinomen
Zusammenfassung: c-Met spielt eine bedeutende Rolle in einer Vielzahl zellulärer Prozesse. Als Protoonkogen unterstützt die Tyrosinkinase aggressives Tumorverhalten, wie z. B. invasives Tumorwachstum und Metastasenbildung. Für einige Subtypen des Nierenzellkarzinoms (NZK) zeigt sich ein mehrfach belegter Zusammenhang zwischen der Höhe der c-Met Expression und dem Krankheitsverlauf bzw. der Prognose. c-Met stellt somit beim NZK einen prognostischen Marker dar.Darüber hinaus wird c-Met in der Ära der personalisierten Medizin als möglicher Angriffspunkt gezielter Therapien eine bedeutende Rolle spielen. Vor allem beim klarzelligen NZK erlangt die duale VEGF und c-Met Tyrosinkinase-Hemmung bei metastasierten, therapierefraktären Tumoren zunehmend klinische Relevanz. Die Bedeutung von c-Met ist bis dato noch nicht gänzlich für alle Subtypen des NZK geklärt. Die Relevanz von c-Met bei den übrigen NZK gilt es noch abschließend zu klären.
- 3 August 2017
- Published by Georg Thieme Verlag KG in TumorDiagnostik & Therapie
- Vol. 38 (06) , 381-385
c-Met Onkogen bei Nierenzellkarzinomen
Zusammenfassung: c-Met spielt eine bedeutende Rolle in einer Vielzahl zellulärer Prozesse. Als Protoonkogen unterstützt die Tyrosinkinase aggressives Tumorverhalten, wie z. B. invasives Tumorwachstum und Metastasenbildung. Für einige Subtypen des Nierenzellkarzinoms (NZK) zeigt sich ein mehrfach belegter Zusammenhang zwischen der Höhe der c-Met Expression und dem Krankheitsverlauf bzw. der Prognose. c-Met stellt somit beim NZK einen prognostischen Marker dar.Darüber hinaus wird c-Met in der Ära der personalisierten Medizin als möglicher Angriffspunkt gezielter Therapien eine bedeutende Rolle spielen. Vor allem beim klarzelligen NZK erlangt die duale VEGF und c-Met Tyrosinkinase-Hemmung bei metastasierten, therapierefraktären Tumoren zunehmend klinische Relevanz. Die Bedeutung von c-Met ist bis dato noch nicht gänzlich für alle Subtypen des NZK geklärt. Die Relevanz von c-Met bei den übrigen NZK gilt es noch abschließend zu klären.
- 11 July 2017
- Published by Springer Nature in Der Pathologe
- Vol. 38 (5) , 430-437
Erwachsenenobduktionen im letzten Jahrzehnt in Deutschland
- 11 July 2017
- Published by Springer Nature in Der Pathologe
- Vol. 38 (5) , 430-437
Erwachsenenobduktionen im letzten Jahrzehnt in Deutschland
- 14 June 2017
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 48 (04) , 336-339
Welche Rolle spielt die Immunonkologie beim Urothelkarzinom aus pathologischer Sicht?
Zusammenfassung: Immuntherapeutika, wie beispielsweise die Programmed death 1-(PD-1-)Antikörper Pembrolizumab und Nivolumab, sind bei mehreren Tumorentitäten, wie z. B. dem malignen Melanom, in Europa bereits in der Erstlinientherapie zugelassen. Nach dem durchschlagenden Erfolg dieser Antikörper bei zahlreichen Tumorarten wird nun auch der mögliche Einsatz in der Uroonkologie erforscht. Die Zulassung des PD-1-Antikörpers Nivolumab für die Therapie des metastasierten Nierenzellkarzinoms setzte in der Uroonkologie einen neuen Meilenstein. Im Mai 2016 wurde dieser Erfolg durch die Zulassung des Programmed death ligand 1 (PD-L1)-Antikörpers Atezolizumab beim fortgeschrittenen Urothelkarzinom fortgeführt. Außerdem laufen derzeit zahlreiche klinische Studien mit anderen Checkpoint-Inhibitoren, welche ebenfalls eine vielversprechende Wirksamkeit beim fortgeschrittenen Urothelkarzinom zeigen.Die Grundlage für den Einsatz dieser Immuntherapeutika bildet unter anderem die immunhistochemische Auswertung des Tumors durch den Pathologen. Um eine einheitliche pathologische Bewertung zu erzielen, besteht aktuell jedoch noch ein erheblicher Standardisierungsbedarf. Bis dato werden sowohl unterschiedliche Bewertungssysteme als auch unterschiedliche Detektionssysteme für ein und denselben Antikörper angewandt. Dadurch wird die Vergleichbarkeit der Studien und damit die Beurteilung der Wirksamkeit der jeweiligen Antikörper erschwert.
- 14 June 2017
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 48 (04) , 336-339
Welche Rolle spielt die Immunonkologie beim Urothelkarzinom aus pathologischer Sicht?
Zusammenfassung: Immuntherapeutika, wie beispielsweise die Programmed death 1-(PD-1-)Antikörper Pembrolizumab und Nivolumab, sind bei mehreren Tumorentitäten, wie z. B. dem malignen Melanom, in Europa bereits in der Erstlinientherapie zugelassen. Nach dem durchschlagenden Erfolg dieser Antikörper bei zahlreichen Tumorarten wird nun auch der mögliche Einsatz in der Uroonkologie erforscht. Die Zulassung des PD-1-Antikörpers Nivolumab für die Therapie des metastasierten Nierenzellkarzinoms setzte in der Uroonkologie einen neuen Meilenstein. Im Mai 2016 wurde dieser Erfolg durch die Zulassung des Programmed death ligand 1 (PD-L1)-Antikörpers Atezolizumab beim fortgeschrittenen Urothelkarzinom fortgeführt. Außerdem laufen derzeit zahlreiche klinische Studien mit anderen Checkpoint-Inhibitoren, welche ebenfalls eine vielversprechende Wirksamkeit beim fortgeschrittenen Urothelkarzinom zeigen.Die Grundlage für den Einsatz dieser Immuntherapeutika bildet unter anderem die immunhistochemische Auswertung des Tumors durch den Pathologen. Um eine einheitliche pathologische Bewertung zu erzielen, besteht aktuell jedoch noch ein erheblicher Standardisierungsbedarf. Bis dato werden sowohl unterschiedliche Bewertungssysteme als auch unterschiedliche Detektionssysteme für ein und denselben Antikörper angewandt. Dadurch wird die Vergleichbarkeit der Studien und damit die Beurteilung der Wirksamkeit der jeweiligen Antikörper erschwert.
- 21 April 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (6) , 1-8
Prognostic impact of PD-1 and its ligands in renal cell carcinoma
Programmed death-1 receptor (PD-1) and programmed death-1 receptor-ligand (PD-L1) have been suggested to play a role as prognostic markers in clear cell renal cell carcinoma (ccRCC). The association between PD-L1 and prognosis seems to be more robust than for PD-1. Further, preliminary analyses suggest that neither PD-1 nor its ligands play a role as prognostic markers in non-clear cell RCC, while the prognostic role of PD-L2 in ccRCC as well as in non-clear cell RCC remains unclear.
- 21 April 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (6) , 1-8
Prognostic impact of PD-1 and its ligands in renal cell carcinoma
Programmed death-1 receptor (PD-1) and programmed death-1 receptor-ligand (PD-L1) have been suggested to play a role as prognostic markers in clear cell renal cell carcinoma (ccRCC). The association between PD-L1 and prognosis seems to be more robust than for PD-1. Further, preliminary analyses suggest that neither PD-1 nor its ligands play a role as prognostic markers in non-clear cell RCC, while the prognostic role of PD-L2 in ccRCC as well as in non-clear cell RCC remains unclear.
- 28 March 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (5) , 1-6
PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
In the context of cancer immunotherapy, PD-1 as well as PD-L1 has been widely studied in renal cell carcinoma (RCC). PD-1 and PD-L1 play a significant role as prognostic markers in clear cell renal cell carcinoma. In contrast, little is known about PD-L2 expression patterns in RCC, especially in rarer subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-L2 expression in chromophobe (ch)RCC. Eighty-one patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for PD-L2 expression by immunohistochemistry. Expression data were associated with clinicopathological parameters and overall survival (OS). Twenty-three (28.4%) patients showed a PD-L2 > median (PD-L2 high) staining intensity. No significant association between clinicopathological parameters and PD-L2 expression was identified. A significant difference between 5- and 10-year OS in dependence of PD-L2 expression was found (PD-L2 low 96.4 and 87.7% vs. PD-L2 high 87.1 and 56%; log rank, p = 0.029). However, in multivariate analysis PD-L2 expression failed to be proofed as an independent prognostic factor. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of PD-L2 in a considerably large cohort of chRCC. Our results showed a significant diminished OS in dependence of PD-L2 expression. This implicates that PD-L2 might play a role as prognostic marker in chRCC demanding further evaluation.
- 28 March 2017
- Published by Springer Nature in Medical Oncology
- Vol. 34 (5) , 1-6
PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
In the context of cancer immunotherapy, PD-1 as well as PD-L1 has been widely studied in renal cell carcinoma (RCC). PD-1 and PD-L1 play a significant role as prognostic markers in clear cell renal cell carcinoma. In contrast, little is known about PD-L2 expression patterns in RCC, especially in rarer subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-L2 expression in chromophobe (ch)RCC. Eighty-one patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for PD-L2 expression by immunohistochemistry. Expression data were associated with clinicopathological parameters and overall survival (OS). Twenty-three (28.4%) patients showed a PD-L2 > median (PD-L2 high) staining intensity. No significant association between clinicopathological parameters and PD-L2 expression was identified. A significant difference between 5- and 10-year OS in dependence of PD-L2 expression was found (PD-L2 low 96.4 and 87.7% vs. PD-L2 high 87.1 and 56%; log rank, p = 0.029). However, in multivariate analysis PD-L2 expression failed to be proofed as an independent prognostic factor. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of PD-L2 in a considerably large cohort of chRCC. Our results showed a significant diminished OS in dependence of PD-L2 expression. This implicates that PD-L2 might play a role as prognostic marker in chRCC demanding further evaluation.
- 29 December 2016
- Published by Springer Nature in Medical Oncology
- Vol. 34 (2) , 15
c-Met in chromophobe renal cell carcinoma
C-Met plays a role as a prognostic marker in clear cell renal cell carcinoma. In addition, recently the tyrosine kinase inhibitor cabozantinib targeting c-Met was approved for the treatment of advanced renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known about c-Met expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of c-Met expression on chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for c-Met expression by immunohistochemistry. Expression data were associated with clinicopathological parameters including patient survival. Eighty-one chRCC patients were eligible for analysis. Twenty-four (29.6%) patients showed a high c-Met expression (c-Methigh, staining intensity higher than median). Our results showed an association between c-Methigh expression and the existence of lymph node metastasis (p = 0.007). No further significant clinicopathological associations with c-Met were identified, also regarding c-Met expression and overall survival. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of c-Met in a considerably large cohort of chRCC. High c-Met expression is associated with the occurrence of lymph node metastasis. This indicates that c-Met might be implicated into metastatic progression in chRCC.
- 29 December 2016
- Published by Springer Nature in Medical Oncology
- Vol. 34 (2) , 15
c-Met in chromophobe renal cell carcinoma
C-Met plays a role as a prognostic marker in clear cell renal cell carcinoma. In addition, recently the tyrosine kinase inhibitor cabozantinib targeting c-Met was approved for the treatment of advanced renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known about c-Met expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of c-Met expression on chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for c-Met expression by immunohistochemistry. Expression data were associated with clinicopathological parameters including patient survival. Eighty-one chRCC patients were eligible for analysis. Twenty-four (29.6%) patients showed a high c-Met expression (c-Methigh, staining intensity higher than median). Our results showed an association between c-Methigh expression and the existence of lymph node metastasis (p = 0.007). No further significant clinicopathological associations with c-Met were identified, also regarding c-Met expression and overall survival. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of c-Met in a considerably large cohort of chRCC. High c-Met expression is associated with the occurrence of lymph node metastasis. This indicates that c-Met might be implicated into metastatic progression in chRCC.
- 30 September 2016
- Published by Springer Nature in Medical Oncology
- Vol. 33 (11) , 1-6
PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Immune checkpoint inhibitors targeting the inhibitory cross talk between tumor and immune cells have been approved for therapy in renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known on PD-1/PD-L1 expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-1 and PD-L1 expression in chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimen was analyzed for PD-1 and PD-L1 expression by immunohistochemistry. Expression data were correlated with clinic-pathological parameters including patient survival. Eighty-one chRCC patients were eligible for analysis, thereof 25 (30.9 %) and 11 (13.6 %) patients were positive for PD-1+ tumor-infiltrating mononuclear cells (TIMCs) and tumoral PD-L1+ expression, respectively. No significant associations were found for PD-1+ TIMC or tumoral PD-L1+ expression and clinical attributes. In addition, no differences in 5- and 10-year overall survival for PD-1− TIMC compared to PD-1+ TIMC (90.5 and 72.2 vs. 100 and 75 %; p = 0.41) and for PD-L1− tumors compared to PD-L1+ tumors (91.9 and 76.4 vs. 100 and 50 %; p = 0.48) were observed. In conclusion, to our knowledge this is the first study to evaluate the prognostic impact of PD-1 and PD-L1 in chRCC. PD-L1 does seem to be expressed in a minority of all chRCC, likewise only a minority of chRCC was infiltrated by PD-1-positive inflammatory cells. Neither PD-1+ TIMC nor tumoral PD-L1+ expression was associated with parameters of aggressiveness or survival.
- 30 September 2016
- Published by Springer Nature in Medical Oncology
- Vol. 33 (11) , 1-6
PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Immune checkpoint inhibitors targeting the inhibitory cross talk between tumor and immune cells have been approved for therapy in renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known on PD-1/PD-L1 expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-1 and PD-L1 expression in chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimen was analyzed for PD-1 and PD-L1 expression by immunohistochemistry. Expression data were correlated with clinic-pathological parameters including patient survival. Eighty-one chRCC patients were eligible for analysis, thereof 25 (30.9 %) and 11 (13.6 %) patients were positive for PD-1+ tumor-infiltrating mononuclear cells (TIMCs) and tumoral PD-L1+ expression, respectively. No significant associations were found for PD-1+ TIMC or tumoral PD-L1+ expression and clinical attributes. In addition, no differences in 5- and 10-year overall survival for PD-1− TIMC compared to PD-1+ TIMC (90.5 and 72.2 vs. 100 and 75 %; p = 0.41) and for PD-L1− tumors compared to PD-L1+ tumors (91.9 and 76.4 vs. 100 and 50 %; p = 0.48) were observed. In conclusion, to our knowledge this is the first study to evaluate the prognostic impact of PD-1 and PD-L1 in chRCC. PD-L1 does seem to be expressed in a minority of all chRCC, likewise only a minority of chRCC was infiltrated by PD-1-positive inflammatory cells. Neither PD-1+ TIMC nor tumoral PD-L1+ expression was associated with parameters of aggressiveness or survival.